S-3 filed May 12, 2026 at 17:27 ET
Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q1 2026 earnings release and 10-Q filing. The company reported $132.6M in cash as of March 31, 2026, with R&D expenses of $6.4M (up from $1.0M YoY) and a net loss of $9.6M. The shelf provides maximum flexibility for future capital raises, but the company states existing cash funds operations through key Phase 2 readouts in 2H 2027 and early 2028, suggesting this is an opportunistic shelf filing rather than an imminent dilutive event.